Interactions between Xenobiotics and DME (XEOTIC)
|
Health or Environmental Toxicant(s) |
Carcinogen |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
Aflatoxin B1 |
Click to Show/Hide the Detail |
Induction |
XEOTIC ID |
XEO00806
XEOTIC Info
|
Gene Form |
mRNA |
Classification |
Carcinogen-mycotoxin |
DME Modulation |
Aflatoxin B1 up-regulates the expression of DME CYP2R1 |
[1] |
Health Hazard/Toxicant |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
1-methyl-4-phenylpyridinium |
Click to Show/Hide the Detail |
Induction |
XEOTIC ID |
XEO01103
XEOTIC Info
|
Gene Form |
mRNA |
Classification |
Health Hazard |
DME Modulation |
1-methyl-4-phenylpyridinium up-regulates the expression of DME CYP2R1 |
[2] |
Natural Product(s), Extract(s) or Medicine(s) |
Natural Mixture |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
Tobacco smoke pollution |
Click to Show/Hide the Detail |
Inhibition |
XEOTIC ID |
XEO00821
XEOTIC Info
|
Gene Form |
Protein |
Classification |
Natural Mixture |
DME Modulation |
Tobacco smoke pollution inhibits the drug-metabolizing activity of DME CYP2R1 |
[3] |
Plant Extract |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
Plant extracts |
Click to Show/Hide the Detail |
Induction |
XEOTIC ID |
XEO01574
XEOTIC Info
|
Gene Form |
Protein |
Classification |
Plant Extract |
DME Modulation |
Plant extracts induces the drug-metabolizing activity of DME CYP2R1 |
[4], [5] |
Pharmaceutical Agent(s) |
Approved/Marketed Drug |
Click to Show/Hide the Full List of Xenobiotics: 3 Xenobiotics
|
Amiodarone hydrochloride |
Click to Show/Hide the Detail |
Induction |
XEOTIC ID |
XEO00277
XEOTIC Info
|
Gene Form |
mRNA |
Classification |
Drug Approved by US FDA |
DME Modulation |
Amiodarone hydrochloride up-regulates the expression of DME CYP2R1 |
[6] |
Cyclosporine |
Click to Show/Hide the Detail |
Induction |
XEOTIC ID |
XEO00241
XEOTIC Info
|
Gene Form |
mRNA |
Classification |
Drug Approved by US FDA |
DME Modulation |
Cyclosporine up-regulates the expression of DME CYP2R1 |
[7], [8] |
Obeticholic acid |
Click to Show/Hide the Detail |
Induction |
XEOTIC ID |
XEO00165
XEOTIC Info
|
Gene Form |
Protein |
Classification |
Drug Approved by US FDA |
DME Modulation |
Obeticholic acid induces the drug-metabolizing activity of DME CYP2R1 |
[9] |
Drug in Phase 1 Clinical Trial |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
Sodium arsenite |
Click to Show/Hide the Detail |
Inhibition |
XEOTIC ID |
XEO00632
XEOTIC Info
|
Gene Form |
mRNA |
Classification |
Highest Clinical Status: Phase 1 |
DME Modulation |
Sodium arsenite inhibits the expression of DME CYP2R1 |
[10] |
Preclinical/Patented Drug |
Click to Show/Hide the Full List of Xenobiotics: 2 Xenobiotics
|
(+)-JQ1 |
Click to Show/Hide the Detail |
Induction |
XEOTIC ID |
XEO00723
XEOTIC Info
|
Gene Form |
mRNA |
Classification |
Drug in Preclinical Study |
DME Modulation |
(+)-JQ1 up-regulates the expression of DME CYP2R1 |
[11] |
GSK-J4 |
Click to Show/Hide the Detail |
Inhibition |
XEOTIC ID |
XEO01324
XEOTIC Info
|
Gene Form |
mRNA |
Classification |
Patented Pharmaceutical Agent |
DME Modulation |
GSK-J4 inhibits the expression of DME CYP2R1 |
[12] |
|
|
|
|
|
|